Walmart's 2.6% Comp Miss Puts Its Pharmacy Problem in View

Walmart reported second-quarter US comparable sales excluding fuel up 2.6%, below the lowest analyst estimate compiled by Bloomberg and the slowest pace in more than six years, sending the shares down as much as 10% intraday Thursday in New York.

Walmart Inc. (WMT) did something last quarter that it almost never does: it missed on sales. US comparable sales excluding fuel — the measure of what stores open at least a year rang up, stripped of gasoline’s price swings — rose 2.6% in the second quarter. That figure came in below the lowest estimate analysts had submitted to Bloomberg, and it is the slowest rate of growth the retailer has posted in more than six years.

The market’s response was blunt. Shares fell as much as 10% intraday Thursday in New York, the sharpest one-day swing since 2022, wiping out the modest year-to-date gain the stock had accumulated through the prior close. The selling has not fully stopped. As of 17:49 GMT on Friday, 21 August 2026, the stock was quoted at 102.96, down 0.85% from a previous close of 103.84, with a session range of 102.15 to 104.28.

A slower quarter than any analyst modelled

Missing consensus is ordinary. Missing the lowest number in the range is not. It means no one on the sell side had built a scenario this soft into their model, which is why the repricing was violent rather than gradual. Walmart trades at a premium partly because it is regarded as the most predictable large-cap retailer in the United States — a company whose comp figure lands inside a narrow band quarter after quarter. When that reputation cracks, the multiple attached to it comes under review immediately.

The company attributed the shortfall primarily to pricing pressure in its pharmacy business. That matters for how investors should read the number. Pharmacy at scale is a business of reimbursement rates and generic drug pricing, not of shopper footfall. Lower prices on prescriptions mechanically drag on comparable sales dollars even if the same number of prescriptions goes out the door — and can drag on them harder than a genuine slowdown in discretionary spending would.

Consumer weakness or a line-item problem

This is the split that will decide where the stock settles. One reading says Walmart is the tell: the largest big-box retailer in the country is decelerating in step with a slow-growing US economy, and if the low-price leader cannot hold its growth rate, discretionary retailers further up the price ladder have a harder road. The other reading says this is a contained margin and mix issue inside one department, with pharmacy pricing as an identifiable, quantifiable culprit rather than evidence of a shopper pulling back.

The lead facts point toward the second interpretation more than the first, because the company named pharmacy pricing as the primary drag. But investors rarely grant that benefit of the doubt on the day of a first miss, and Thursday’s move shows it. Poonam Goyal, Senior US Retail Analyst for Bloomberg Intelligence, gave her read on the print in an interview with Bloomberg Markets.

The stock is falling into a rising tape

Context sharpens the picture. Walmart declined on Friday while the broad market advanced. The S&P 500, tracked by SPY, was at $765.75, up 0.41% on the day from a previous close of $762.60. The Nasdaq 100 proxy QQQ stood at $713.64, up 0.38%. The Dow 30 tracker DIA was the strongest of the three at $531.46, up 0.75% from $527.51.

That divergence is the useful signal. Had this been read as a macro warning about the American consumer, the retail complex and the indices would be under pressure alongside Walmart. They are not. Equity markets were higher across all three major benchmarks while Walmart continued to leak. For now, the tape is treating this as a Walmart problem rather than an economy problem.

What is worth tracking from here

Had this been read as a macro warning about the American consumer, the retail complex and the indices would be under pressure alongside Walmart.

Several things will resolve the ambiguity over the coming weeks and quarters.

Whether pharmacy pricing persists. Reimbursement compression tends to be structural rather than one-off. If the same headwind reappears next quarter, the 2.6% figure stops looking like an aberration and starts looking like a run rate.
Comparable sales excluding pharmacy. Any disclosure that isolates general merchandise and grocery from the pharmacy drag would settle the debate about whether the core shopper is spending less.
Whether the stock holds Thursday’s low. The shares have already taken out the year-to-date gain. The 102.15 session low on Friday is the near-term reference point traders will watch.
Read-across to other retailers. If competing big-box and grocery names post comparable deceleration in their own reports, the macro reading gains weight. If they do not, Walmart’s miss stays company-specific.

Why a low-single-digit comp still matters

A 2.6% comparable sales increase is growth, not contraction. In isolation it would not alarm anyone. The problem is the gap between that number and what the market had priced in — and the fact that it is the weakest such print in more than six years, a stretch that covers a pandemic, a supply-chain crisis and a bout of high inflation. Walmart grew through all of it faster than it did this quarter.

For shareholders, the practical question is not whether Walmart is a healthy business. It is whether a company valued for consistency deserves the same valuation once consistency has been publicly broken. Thursday’s 10% intraday drop was the market’s first attempt at answering that. Friday’s continued softening, against three rising benchmarks, suggests the answer is still being worked out.

Key facts

WMT last trade: 102.96, -0.85%, as of 17:49 GMT, 21 Aug 2026
US comp sales ex-fuel: +2.6% in Q2, below the lowest Bloomberg-compiled estimate
Peak intraday drop: As much as 10% Thursday, the most since 2022
Primary drag cited: Pricing pressure in the pharmacy business

Frequently asked questions

What exactly did Walmart miss on?

Walmart’s US comparable sales excluding fuel rose 2.6% in the second quarter. That was below the lowest analyst estimate compiled by Bloomberg, meaning no analyst had modelled a result this soft. It is also the slowest rate of comparable sales growth the retailer has recorded in more than six years, which is why the reaction was outsized.

Why did the pharmacy business cause the shortfall?

Walmart pointed to pricing pressure in pharmacy as the primary drag. Pharmacy revenue depends heavily on reimbursement rates and drug pricing, so lower prices reduce sales dollars even when prescription volumes hold steady. That makes the miss partly a pricing and mix issue within one department rather than straightforward evidence of weaker shopper demand.

How far has the stock fallen?

Walmart shares dropped as much as 10% intraday on Thursday in New York, the largest such move since 2022, erasing a modest year-to-date gain measured through the previous day’s close. The decline continued into Friday, with the stock quoted at 102.96, down 0.85% from a prior close of 103.84, as of 17:49 GMT on 21 August 2026.

Does this mean the US consumer is weakening?

It is not settled. Walmart named pharmacy pricing as the main cause, which points to a company-specific issue. Broader markets also rose on Friday while Walmart fell, suggesting investors are not yet treating the print as a macro warning. Reports from other large retailers will show whether the deceleration is industry-wide.

How did the broader market trade on the same day?

All three major US benchmarks were higher. The S&P 500 tracker SPY stood at $765.75, up 0.41%; the Nasdaq 100 proxy QQQ was at $713.64, up 0.38%; and the Dow 30 tracker DIA was at $531.46, up 0.75%. Walmart declining into a rising tape underlines the company-specific nature of the move.

What should investors watch next?

Whether pharmacy pricing pressure persists into the next quarter, whether Walmart discloses comparable sales stripped of pharmacy so the core shopper trend is visible, whether the shares hold Friday’s 102.15 session low, and whether competing big-box and grocery chains report similar deceleration in their own results.

Sources

Walmart Shares Extend Decline After Rare US Sales Miss — Bloomberg Markets

Photo: Jose Ismael Espinola · Pexels Licence — source